DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rks4jn/medipoint) has announced the addition of the "MediPoint: In-Vitro Colorectal Cancer Screening Tests - Global Analysis and Market Forecasts" report to their offering.
The major feature of the in-vitro colorectal cancer (CRC) screening testing market is the current domination of fecal occult blood (FOB) tests, by a large variety of manufacturers, with no clear market leader. Increasingly, immuno-FOB tests are preferred over the very dated and obsolete guaiac FOB test.
According to The authors's forecast, in 2013, FOB tests account for 94% of the market, which is valued at $333m. Despite a lack of any recommendation from published CRC screening guidelines, emerging DNA tests for CRC have gained some ground, accounting for 5.7% of the market. However, this share is distorted by the relatively high price of these tests, compared with FOB tests. In 2012, 50 million FOB tests were carried out, compared to 60.748 DNA tests globally.
FOB tests are used in the major markets (APAC, US and 5EU), but are not used to any significant extent in South America, due to a lack of any organized CRC screening program.
While the in-vitro CRC screening market is defined by a large number of fecal occult blood tests, produced by a great number of manufacturers, three test producers, Eiken Chemical, Beckman Coulter and Immunostics, account for 49% of the in-vitro CRC screening market, largely through positioning in the US, French, the UK and Japanese markets.
Significant Unmet Needs
Test accuracy remained a significant unmet need, in all markets. FOB tests have a significant false positive result rate, which creates a heavy burden on diagnostic colonoscopy services.
Patient aversion to stool samples is another major unmet need. Poor patient compliance with FOB tests is thought by physicians to be due to an inability to comply with specific dietary instructions, cultural aversion and a lack of awareness of the importance of testing.
Adoption of new screening tests, which test for DNA biomarkers indicative of early-stage CRC, will increase compliance, because they will be more accessible to patients, via their physician. These tests are expected to be more accurate, resulting in a higher percentage of patients referred for a diagnostic colonoscopy being diagnosed with CRC. Compliance will increase, resulting in more people being screened for CRC.
The overall costs of CRC treatment will be driven down, due to increased diagnosis of CRC at an early stage, when it is most easily treatable, and at a lower cost. The number of screening colonoscopies will continue to increase, but will level off over time, since a significant portion of the CRC screening population cannot undergo a screening colonoscopy. Increasingly, the colonoscopy will become regarded as a tool to confirm the diagnosis of CRC indicated by a DNA test.
Key Topics Covered:
List of Tables
List of Figures
Current and Future Players
Market Drivers, Opportunities and Barriers
Country Outlooks & Forecasts
Fujirebio (Miraca Holdings)
MDx Health (was OncoMethylome)
Oncocyte (Bio Time)
For more information visit http://www.researchandmarkets.com/research/rks4jn/medipoint
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.